Kymera Therapeutics, Inc. (KYMR)

Baker Bros. Advisors added 2,005,813 shares of Kymera Therapeutics; the estimated transaction value was $135.45 million.

WATERTOWN, Mass. , Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026.

Rock Springs Capital Management bought 46,497 shares of Kymera Therapeutics in the fourth quarter, with an estimated trade value of $3.14 million (based on quarterly average pricing). Meanwhile, the quarter-end position value increased by $13.17 million, reflecting share additions and price movement.

Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) has been given a consensus recommendation of "Buy" by the twenty-two brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nineteen have issued a buy recommendation and two have assigned a strong buy recommendation to the

Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.

SG Americas Securities LLC lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 61.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,432 shares of the company's stock after selling 13,633 shares during the period.

Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026 Well-capitalized with $1.6 billion 1 in cash and runway into 2029 Kymera to present its 2026 objectives at the J.P. Morgan 44 th Annual Healthcare Conference today at 9:00 a.m.

Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.

Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $78.06, for a total value of $2,341,800.00. Following the completion of the transaction, the chief executive officer directly owned 663,077 shares

Insider buying can be one of the cleanest “follow-the-money” signals in the market. Over the past month or so, three names have stood out for $100 million-plus buying tied to prominent funds and well-known professional investors.

In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.

Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and

China Universal Asset Management Co. Ltd. lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 77.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,079 shares of the company's stock after acquiring an additional 10,052 shares

KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.